Suvorexant (Belsomra) for Insomnia.

نویسنده

  • Andrea R Gauld
چکیده

Suvorexant carries a slight risk of abuse. Events that suggested possible abuse were identified in 3% to 4% of patients in clinical trials.2,3 Suvorexant is a central nervous system depressant. Rare side effects include sleep paralysis, hypnagogic hallucinations, and mild cataplexy, consisting of brief periods of leg weakness.2 Suvorexant should be avoided in patients with depression because it may worsen symptoms; patients with severe depression were excluded from clinical trials. It should also not be used in patients with narcolepsy, obstructive sleep apnea, or severe chronic obstructive pulmonary disease. It is a U.S. Food and Drug Administration pregnancy category C drug. It is unknown whether suvorexant is excreted in human breast milk.1

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant

Insomnia, a highly prevalent disorder, can be detrimental to patients' overall health and worsen existing comorbidities. Patients may have acute episodes of insomnia related to a traumatic event, but more commonly insomnia occurs chronically. While proper sleep hygiene and behavioral therapy play important roles in the nonpharmacologic management of short-term and chronic insomnia, medications ...

متن کامل

WHO downgrades Tamiflu after reviewing evidence

Editorial WHO downgraded oseltamivir (Tamiflu) New Products Hypnotic (sleeping pill), suvorexant (brand name Belsomra) A substance that causes narcolepsy and cataplexy Teriparatide More harm than benefit: Review Insomnia, Optimal Sleep Duration and Harm of Sleeping pills Pneumonia caused by proton pump inhibitors (PPI) (1) meta-analysis (2) Critical appraisal of a study CONTENTS (December 2017,...

متن کامل

Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

OBJECTIVE We performed a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials evaluating suvorexant for primary insomnia. METHODS Relevant studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations through June 27, 2015. We performed a systematic review and meta-analysis of suvorexant trial efficacy and s...

متن کامل

Suvorexant, a dual orexin receptor antagonist for the management of insomnia.

Suvorexant, a dual orexin receptor antagonist for the management of insomnia.

متن کامل

Suvorexant: a promising, novel treatment for insomnia

Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • American family physician

دوره 93 12  شماره 

صفحات  -

تاریخ انتشار 2016